US-based healthcare consulting firm ADVI Health has acquired Partnership for Health Analytic Research (PHAR), which provides consulting and research services in the life science industry.
PHAR is a health technology assessment (HTA) and health economics and outcomes research (HEOR) consultancy that provides data-driven insights to sponsors and clients.
The acquisition will provide ADVI’s strategic analytics, value, and economics (SAVEs) team with new data analysis and value strategy capabilities.
It will add significant HTA/HEOR, primary research, literature review, patient registry expertise, and capabilities from PHAR, said ADVI Health.
ADVI CEO Marc Samuels said: “As the healthcare landscape continues to evolve, so do our clients’ needs. With decades of experience and deep-bench knowledge, PHAR brings a depth of expertise that complements our SAVEs and Market Access teams.”
ADVI is a life sciences data and consulting services firm, and a strategic consulting partner to the healthcare and life sciences ecosystem.
The company serves clients across managed services, MedTech, pharma, and precision medicine, through its offices in Austin, Chicago, San Francisco, and Washington DC.
ADVI said the acquisition of PHAR will support its goal to become a go-to-market partner for life sciences innovators worldwide.
With the integration of PHAR’s data analytics experts, ADVI can expand its work with the evidence behind clinical and retrospective value assessments.
PHAR CEO and founder Michael Broder said: “We are looking forward to working across solution areas and learning new ways to use our data to create more impactful results for the clients we have had for so many years and the new ones we will meet through our partnership with ADVI.
“With the growing number of novel therapeutics coming to market, it is more important than ever that we can use the data available to show the true value of these products, especially when it comes to brand launch, enabling access to on-market products, and bolstering life cycle performance.”
